Manufacturer's Drug Interaction and Postmarketing Adverse Event Data: What Are Appropriate Uses?

Author： Kraft W.K.   Waldman S.A.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.24, Iss.9, 2001-01, pp. : 637-643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?

By Ozdemir V.  

Drug Safety, Vol. 24, Iss. 2, 2001-01 ,pp. : 75-85

Adis International

Access to resources Recommend Favorite

Drug pricing: what's to be done?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 318, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

What Can Consumer Adverse Drug Reaction Reporting Add to Existing Health Professional-Based Systems?: Focus on the Developing World

By Fernandopulle R.B.M.   Weerasuriya K.  

Drug Safety, Vol. 26, Iss. 4, 2003-01 ,pp. : 219-225

Adis International

Access to resources Recommend Favorite

What Counts in Data Mining?

By Hauben Manfred   Patadia Vaishali K.  

Drug Safety, Vol. 29, Iss. 10, 2006-01 ,pp. : 827-832

Adis International

Access to resources Recommend Favorite

Quantifying Adverse Drug Events: Are Systematic Reviews the Answer?

By Mahyar Etminan   Bruce Carleton   Paula A. Rochon  

Drug Safety, Vol. 27, Iss. 11, 2004-01 ,pp. : 757-761

Adis International

Access to resources Recommend Favorite